4 results match your criteria: "Baillieston Health Centre[Affiliation]"
Diagnostic accuracy of the Thessaly test, standardised clinical history and other clinical examination tests (Apley's, McMurray's and joint line tenderness) for meniscal tears in comparison with magnetic resonance imaging diagnosis.
Health Technol Assess
August 2015
Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK.
Article Synopsis
- Non-invasive diagnosis of meniscal tears is challenging, with MRI being costly and often revealing incidental findings; many simple physical exams exist as alternatives.
- The study aimed to assess the diagnostic accuracy of the Thessaly test and its potential to reduce reliance on MRI or arthroscopy for suspected meniscal tears.
- Results showed the Thessaly test had moderate sensitivity (66%) and low specificity (39%) by primary care clinicians, indicating it may not reliably diagnose meniscal tears on its own, although other physical tests had similar accuracy rates.
The efficacy and safety of grepafloxacin were compared with clarithromycin in a randomized, double-blind, multicentre clinical trial of 805 patients with acute bacterial exacerbations of chronic bronchitis (ABECB). Patients were randomized to receive grepafloxacin 400 mg od for either 5 (n = 273) or 10 days (n = 268) or clarithromycin 250 mg bd for 10 days (n = 261). Patients were assessed pre-treatment, 3-5 days during treatment, 1-3 days post-treatment and at follow-up (21-28 days post-treatment).
View Article and Find Full Text PDFRandomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis.
J Antimicrob Chemother
December 1997
Baillieston Health Centre, Department of Postgraduate Medical Education, University of Glasgow, UK.
This randomized, multicentre, double-blind, double-dummy study compared the efficacy and safety of grepafloxacin and amoxycillin in acute bacterial exacerbations of chronic bronchitis (ABECB). Patients were randomized to receive grepafloxacin 400 mg or 600 mg od, or amoxycillin 500 mg tds, for 7 or 10 days. The trial recruited 656 patients, of whom 566 (86%) completed the study.
View Article and Find Full Text PDFNisoldipine CC: clinical experience in hypertension.
Cardiology
April 1997
Baillieston Health Centre, Glasgow, UK.
Nisoldipine coat core (CC) is a long-acting formulation of the dihydropyridine calcium channel blocker nisoldipine, suitable for once-daily administration in the treatment of patients with hypertension. Data are reported from three randomized, controlled trials. In two of these, nisoldipine CC was shown to be equivalent in efficacy and tolerability to atenolol in patients with mild to moderate hypertension and to enalapril in elderly patients with hypertension.
View Article and Find Full Text PDF